EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Regulation FD DisclosureItem 7.01
EyeGate Pharmaceuticals, Inc. (the “Company”) hereby furnishes the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company will use at the Ophthalmology Innovation Summit at AAO, being held November 9, 2017 at The Hyatt Regency in New Orleans, Louisiana, at which Stephen From, President and Chief Executive Officer of the Company, will be presenting at approximately 9:30 a.m. Central Time.
The information furnished to Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
The information furnished in this report, including Exhibit 99.1, shall not be deemed to constitute an admission that such information or exhibit is required to be furnished to Regulation FD or that such information or exhibit contains material information that is not otherwise publicly available. In addition, the Company does not assume any obligation to update such information or exhibit in the future.
| Item 7.01. | Financial Statements and Exhibits. |
The Company hereby furnishes the following exhibit:
| 99.1 | Presentation of the Company, dated as of November 9, 2017. |
EYEGATE PHARMACEUTICALS INC ExhibitEX-99.1 2 tv479071_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Two Versatile Platforms Moving Towards Commercialization Some of the matters discussed in this presentation contain forward – looking statements that involve significant risks and uncerta inties,…To view the full exhibit click here
About EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG)
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.